浙江海昇药业股份有限公司 证券代码：920656 证券简称：海昇药业 公告编号：2025-125 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 4 日 2.会议召开地点：衢州市高新技术产业园区华阳路 36 号二楼会议室 3.会议召开方式：现场方式 4.发出董事会会议通知的时间和方式：2025 年 11 月 22 日以书面方式发出 5.会议主持人：董事长叶山海先生 6.会议列席人员：公司副总经理、董事会秘书彭红江 7.召开情况合法合规的说明： 本次董事会会议召集、召开、议案审议程序等方面符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 （二）会议出席情况 会议应出席董事 5 人，出席和授权出席董事 5 人。 二、议案审议情况 （一）审议通过《关于使用闲置自有资金进行现金管理的议案》 1.议案内容： 具体内容详见公司于 2025 年 12 月 4 日在北京证券交易所信息披露 ...

Group 1 - The average return of 11 theme funds on the Beijing Stock Exchange (BSE) reached 52.12% in 2025, indicating a strong performance and potential for diversified investor participation as the two-year fixed-open products become available for subscription and redemption [1][19][20] - The number of public fund institutions investing in BSE stocks increased to 29 by the end of 2024, a year-on-year growth of 31.82%, with the number of heavily invested companies rising from 34 to 41 in the first three quarters of 2025 [11][12] - The BSE's market performance shows a shift towards diversified investment styles, with a focus on emerging industries such as intelligent connected new energy vehicles, commercial aerospace, low-altitude economy, and robotics [1][31] Group 2 - The BSE 50 Index reported a value of 1,387.70 points, with a week-on-week increase of 0.75%, while the BSE specialized and new index reached 2,317.70 points, up 0.79% [2][43] - The TTM PE ratios for various sectors on the BSE include high-end equipment at 38.37X, information technology at 84.54X, and chemical new materials at 42.21X, indicating sector-specific valuation trends [2][33] - The top ten companies by market value held by funds on the BSE as of Q3 2025 include Jinbo Bio, Naconoer, and Better Energy, with significant changes in holdings reflecting market dynamics [22][23][24] Group 3 - The BSE's passive index fund scale has seen significant growth, with the BSE 50 Index fund size reaching 128.93 billion yuan by November 28, 2025, and the number of tracking products increasing to 68 [13][16] - The fund holdings on the BSE show that 59.17% of companies have a market value between 2-5 billion yuan, while 49.17% of companies reported a net profit of less than 50 million yuan in 2024 [27][29] - The industry allocation preferences of funds on the BSE are similar to those on the dual innovation board, with the top five sectors being machinery, hardware equipment, electrical equipment, automotive parts, and software services [31][32]

Investment Rating - The report assigns an "Accumulate" rating for the company [1] Core Views - The company is a leading player in the sulfonamide raw material drug industry, with a comprehensive product chain and competitive advantages. It has achieved significant revenue and net profit growth in the first three quarters of 2025, with revenue reaching 164 million yuan, a year-on-year increase of 40.89%, and net profit attributable to shareholders of 49.05 million yuan, up 47.16% year-on-year [3][49] - The company has established strong barriers to entry in the market through its technical capabilities and stable customer relationships, allowing it to expand into high-value human pharmaceutical raw materials [4][30] - The regulatory environment is improving, which is expected to enhance the competitive landscape, with the company being less affected by the "antibiotic ban" and "reduction" policies [5] Summary by Sections Company Overview - The company focuses on the research, production, and sales of veterinary and pharmaceutical raw materials and intermediates, recognized as one of the most competitive enterprises in the sulfonamide raw material drug sector [3][14] - It has been designated as a national high-tech enterprise since 2016, maintaining its status through continuous innovation and quality control [3][23] Financial Performance - In the first three quarters of 2025, the company reported a revenue of 164 million yuan, a 40.89% increase year-on-year, and a net profit of 49.05 million yuan, reflecting a 47.16% growth [49] - The projected net profits for 2025-2027 are estimated at 66 million, 76 million, and 87 million yuan, respectively, with corresponding EPS of 0.66, 0.76, and 0.87 yuan per share [3] Market Position and Competitive Advantage - The company has a deep customer resource barrier, with long-term stable relationships with major clients, which enhances its pricing power and profit margins [30] - It has received multiple certifications for its products, including approvals from the National Medical Products Administration and the European Medicines Agency, which facilitate entry into high-end markets [4][34] Industry Trends - The raw material drug market in China reached 426.5 billion yuan in 2021, with a growth rate of 10.98% from 2018 [5] - The veterinary raw material drug market is showing signs of recovery, with improved supply-demand dynamics and rising prices for key products [39][41]

证券代码：920656 证券简称：海昇药业 公告编号：2025-121 浙江海昇药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 浙江海昇药业股份有限公司（以下简称"公司"）于近日收到保荐机构长江证 券承销保荐有限公司（以下简称"长江保荐"）出具的《长江证券承销保荐有限公 司关于变更持续督导保荐代表人的说明》。 长江保荐作为公司向不特定合格投资者公开发行股票并在北京证券交易所上市 的保荐机构，委派王新洛先生和王海涛先生担任公司持续督导保荐代表人，持续督 导期为 2024 年 2 月 2 日至 2027 年 12 月 31 日。 由于原保荐代表人王海涛先生因工作变动原因，不再负责公司持续督导工作。 为保证持续督导工作的有序进行，长江保荐决定委派古小刚先生（简历详见附件） 接替王海涛先生担任持续督导保荐代表人，继续履行持续督导职责。 本次保荐代表人变更不影响长江保荐对公司的持续督导工作，变更后，长江保 荐负责公司持续督导工作的保荐代表人为王新洛先生、古小刚先 ...

证券代码：920656 证券简称：海昇药业 公告编号：2025-120 2．本年授权现金管理 公司于 2025 年 5 月 16 日召开第三届董事会第二十二次会议、第三届监事会 第二十次会议，于 2025 年 6 月 4 日召开 2025 年第二次临时股东会，审议通过 了《关于使用部分闲置募集资金进行现金管理的议案》，在确保资金安全、不影 响募集资金投资项目建设的前提下，公司拟使用额度不超过人民币 2.8 亿元（含 本数）的闲置募集资金进行现金管理，在上述额度范围内资金可以循环滚动使 用，并授权公司董事长行使相关投资决策权并签署相关文件，财务负责人负责 具体组织实施及办理相关事宜。具体内容详见公司于 2025 年 5 月 19 日在北京 证券交易所信息披露平台（www.bse.cn）披露的《关于使用部分闲置募集资金 进行现金管理的公告》（公告编号：2025-050）。 （二）本次委托理财披露的标准 浙江海昇药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 ...

证券代码：920656 证券简称：海昇药业 公告编号：2025-119 浙江海昇药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （二）本次委托理财披露的标准 根据《北京证券交易所股票上市规则》中相关规定，交易的成交金额占上市 公司最近一期经审计净资产的 10%以上且超过 1,000.00 万元的应当予以披露。 本次自有资金购买的理财产品金额为 6,000 万元，截至目前，公司自有资金 购买的理财产品未到期余额为 11,500 万元。 二、 本次委托理财情况 | 受托方 | | 产品 | 产品名称 | 产品金 额（万 | 预计年化收 | 产品 | 收益 | 投资 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 类型 | | 元） | 益率（%） | 期限 | 类型 | 方向 | 来源 | | 杭 | 州 | 银 行 | 杭州银行"添利 | ...

Group 1: Industry Overview - The pet economy in Zhejiang Province aims to exceed 30 billion yuan by 2027 and 50 billion yuan by 2030, establishing itself as a national innovation hub for pet economy and a major producer of pet food and supplies [1] - The pet industry is experiencing rapid growth, with various cities like Suzhou and Wuxi implementing supportive policies to enhance the pet economy [1] - The global OTC pet medicine market is projected to grow from 9.8 billion USD in 2025 to 16.4 billion USD by 2034, with a CAGR of 5.9% [4] Group 2: Company Positioning - Haisheng Pharmaceutical is a key player in the veterinary medicine sector, possessing the longest supply chain for sulfonamide raw materials and a comprehensive product range [2] - The company is actively developing pet raw materials and enhancing existing product quality while expanding production capacity to strengthen its competitive edge [1][2] - Haisheng Pharmaceutical has established three research pipelines for pet raw materials, focusing on improving synthesis processes and increasing product variety [2] Group 3: Financial Performance - In the first three quarters of 2025, Haisheng Pharmaceutical reported revenue of 164 million yuan, a year-on-year increase of 40.89%, and a net profit of 49.05 million yuan, up 47.16% [3] - The company achieved a third-quarter revenue of 62.99 million yuan, reflecting a 38.94% year-on-year growth, with a net profit increase of 89.48% [3] - The significant improvement in cash flow, with a net increase of 1527.50%, indicates enhanced profitability and provides a solid foundation for business expansion [3]

Investment Rating - The investment rating for the pharmaceutical industry is "Accumulate (Maintain)" [1] Core Views - The report indicates that the company has shown continuous growth in revenue and profit, with a 40.89% increase in revenue to 164 million yuan and a 47.16% increase in net profit to 49.04 million yuan for the first three quarters of 2025 [5][8] - The company's gross margin and net margin have improved, with gross margin at 42.70% (up 2.59 percentage points) and net margin at 29.94% (up 1.28 percentage points), reflecting enhanced profitability and operational efficiency [5][8] - The company is expected to benefit from the recovery in the industry and has a diversified product line, particularly in the pet medicine sector, which is anticipated to drive future growth [5][8] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 164 million yuan, a year-on-year increase of 40.89%, and a net profit of 49.04 million yuan, up 47.16% [5][8] - The third quarter alone saw a revenue of 62.99 million yuan (up 38.94%) and a net profit of 18.72 million yuan (up 89.48%) [5][8] Market Position and Strategy - The company has a strong market presence with products covering Europe, Asia, and South America, and is deepening collaborations with international clients [5][8] - New products are expected to contribute to revenue growth, and the company is focusing on expanding its international market presence [5][8] Financial Health - As of the end of Q3 2025, the company reported total assets of 706 million yuan, with a low debt ratio of 3.26%, indicating a strong financial position [5][8] - The report forecasts revenue growth for 2025-2027, with expected revenues of 227.04 million yuan, 255.81 million yuan, and 289.01 million yuan, representing growth rates of 36.60%, 12.67%, and 12.98% respectively [9][11]

Policy Developments - The "14th Five-Year Plan" emphasizes accelerating the construction of a Healthy China, implementing a health-first development strategy, and enhancing public health capabilities [2] - The plan aims to improve the healthcare system, promote the integration of traditional Chinese and Western medicine, and support the development of innovative drugs and medical devices [2] Drug and Device Approvals - Shanghai Pharmaceuticals' bromide pyridostigmine sustained-release tablets have received production approval from the National Medical Products Administration, which is expected to enhance market share and competitiveness [3] - The company has invested approximately RMB 16.009 million in the research and development of this drug [3] Financial Reports - Fosun Pharma reported a 26% year-on-year increase in net profit for the first three quarters of 2025, despite a 4.91% decline in revenue [4] - Haisheng Pharmaceutical achieved a 40.89% increase in revenue and a 47.16% increase in net profit for the first three quarters of 2025 [5] Capital Market Activities - New Tian Di has entered a strategic cooperation agreement with Nanjing Zhihe Pharmaceutical to develop GLP-1 long-acting peptide innovative drugs [6][7] - WuXi AppTec signed strategic cooperation memorandums with NEOM and the Saudi Ministry of Health to explore localized new drug R&D and production services [8] Industry Events - The results of the 11th batch of national drug centralized procurement were announced, including 55 drugs aimed at stabilizing clinical needs and ensuring quality [9][10] - The procurement process has raised the qualification thresholds for bidding companies and aims to prevent collusion in pricing [10] Intellectual Property Developments - The Deputy Director of the National Intellectual Property Administration of China met with representatives from the International Pharmaceutical Alliance to discuss patent protection and dispute resolution mechanisms [11] Shareholder Actions - BioVeda, a major shareholder of AoJing Medical, has completed a share reduction plan, selling 1.3555 million shares, which represents 1% of the company's total equity [12]

Core Viewpoint - Haisheng Pharmaceutical reported significant growth in revenue and net profit for the third quarter of 2025, driven by increased sales, improved bank investment returns, and government subsidies [1] Financial Performance - The company achieved operating revenue of 164 million yuan, representing a year-on-year increase of 40.89% [1] - The net profit attributable to shareholders reached 49.05 million yuan, up 47.16% year-on-year [1] - In the third quarter alone, the net profit attributable to shareholders was 18.72 million yuan, showing a remarkable growth of 89.48% compared to the same period last year [1] Investment and Assets - The company's construction in progress increased by 45.40% compared to the beginning of the year, primarily due to investments in new production lines, laying a foundation for future development [1] - A decrease in cash holdings was noted, attributed to the purchase of large bank financial products, with trading financial assets at the end of the period amounting to 360 million yuan [1]